Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma

Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Aakash, Bisno, Daniel I., Patel, Hiren V., Ghodoussipour, Saum, Saraiya, Biren, Mayer, Tina, Singer, Eric A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276975/
https://www.ncbi.nlm.nih.gov/pubmed/34263255
http://dx.doi.org/10.33696/cancerimmunol.3.047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276975/
https://www.ncbi.nlm.nih.gov/pubmed/34263255
http://dx.doi.org/10.33696/cancerimmunol.3.047

Ejemplares similares